Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have signed an IRB-approved informed consent.~2. Patients must have histologically confirmed locally advanced or metastatic breast cancer.~3. Patients must be HER2-negative.~4. Patients must have measurable disease, as defined by the RECIST criteria.~5. Patients may have received prior adjuvant chemotherapy for breast cancer, including taxane-containing regimens, provided this treatment was completed at least 12 months prior to enrollment.~6. Patients must be \<18 years of age.~7. Patients must have an ECOG Performance Status of 0 or 1.~8. Patients' estimated life expectancy must be at least 12 weeks.~9. Patients must have adequate liver functions defined as: total bilirubin within normal limits and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 X upper limit of normal (ULN) (or \< 5 X ULN for patients with liver involvement).~10. Patients must have alkaline phosphatase ≤ 2.5 X ULN. Alkaline phosphatase may be \> 2.5 x ULN if bone metastasis is present in the absence of liver metastasis, and the patient's bilirubin ≤ ULN.~11. Patients must have adequate renal function defined as: creatinine ≤ 1.5 mg/dL.~12. Patients must have adequate bone marrow function, including absolute neutrophil count (ANC) \>1500/µL, platelet count \>100,000/µL, and hemoglobin \>9 g/dL.~13. Patients must have a normal baseline left ventricular ejection fraction (LVEF).~14. Patients must be normotensive. Patients taking anti-hypertensive medication must have blood pressure controlled and not greater than 140/90.~15. International Normalized Ratio (INR) \< 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits.~16. Patients must either be not of child bearing potential or have a negative serum pregnancy test within 7 days prior to registration. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal for at least 12 months.~17. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for a reasonable time thereafter.~18. Patients must be willing and able to comply with scheduled visits, treatment plan and laboratory testing, and be accessible for follow-up.~Exclusion Criteria:~1. Patients who have received prior chemotherapy for the treatment of locally advanced or metastatic breast cancer.~2. Patients who have received prior Abraxane or Nexavar.~3. Patients who have a history of hypersensitivity or a suspected allergy to taxanes, any of the components in taxanes, Abraxane, or Nexavar.~4. Patients with serious intercurrent medical or psychiatric illness, including serious active infection.~5. Patients with untreated or active brain metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.~6. Patients with a history of thrombosis.~7. Patients with thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.~8. Patients with symptomatic congestive heart failure or a baseline echocardiogram with LVEF \< ULN.~9. Patients with congestive heart failure \> class II New York Heart Association (NYHA). Patients must not have unstable angina (anginal symptoms at rest), or new onset angina (began within the last 3 months), or myocardial infarction within the past 6 months.~10. Patients with cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.~11. Patients with a history of, or active, bowel perforation or inflammatory bowel disease.~12. Patients with active peptic ulcer disease or symptoms to suggest possible ulcer (discontinuation of chronic NSAID therapy advised, or if not possible, use of proton-pump inhibitors recommended.)~13. Patients planning to receive any concurrent therapy to treat locally advanced or metastatic breast cancer during the study treatment period.~14. Any patient who is pregnant or lactating.~15. Patients with proteinuria \> +1 by baseline dipstick, or if +2, 24-hour urine total protein \> 250 mg.~16. Patients who have undergone major surgery, open biopsy, or significant traumatic injury within 28 days, or minor surgery within 14 days. (The placement of a Mediport or other vascular access device is permitted if performed at least 7 days prior to registration).~17. Patients with \> Grade 2 peripheral neuropathy (NCI-CTC v3.0) or any painful neuropathy.~18. Patients who have experienced any type of bone fracture within 12 months or who have undergone joint replacement surgery within 6 months.~19. Patients with a serious non-healing wound.~20. Patients with known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.~21. Patients requiring anticoagulants (with the exception of low-dose Coumadin, ASA, Plavix or Heparin for maintenance of vascular access patency).~22. Patients with evidence or history of bleeding diathesis or coagulopathy.~23. Patients experiencing any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug.~24. Patients with pulmonary hemorrhage/bleeding event \> CTCAE Grade 2 within 4 weeks of first dose of study drug.~25. Patients with any condition that impairs a patient's ability to swallow whole pills or patients with any malabsorption problems.~26. Patients who use St. John's Wort or rifampin (rifampicin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).